Clinical trials: Aphasia, Nonfluent
Alzheimer's Disease, Primary Progressive Non-fluent Aphasia
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
The purpose of this study is to determine safety, tolerability, and pharmacokinetics/dynamics of a ketogenic dietary supplement containing medium chain triglycerides (MCTs) in patients with Alzheimer disease (AD).
- Conditions
- Alzheimer's Disease, Primary Progressive Non-fluent Aphasia, Frontotemporal Dementia (FTD)
- Trial name
- MINT-01 (NCT02912936)
- Testing
- Ketogenic medium chain triglyceride drink (MCT drink)
- Where
- Canada
- Volunteers
- 43 people
- Sponsor
- University of British Columbia
Stroke, Aphasia, Non-fluent
rTMS and Multi-Modality Aphasia Therapy for Post-Stroke Aphasia
Many stroke survivors experience aphasia, a loss or impairment of language affecting the production or understanding of speech. One common type of aphasia is known as non-fluent aphasia.
- Trial name
- TMAT (NCT04901156)
- Testing
- 1Hz inhibitory rTMS, Multi-Modality Aphasia Therapy (M-MAT)
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University of Calgary
Aphasia, Broca, Aphasia, Wernicke
Remote Neurobased Approach to Aphasia Therapy
The purpose of this study is the development and validation of an evidence-based mobile application, based on the core premises of Intensive Language-Action Therapy (ILAT) for aphasia, for the training and improvement of chronic…
- Conditions
- Aphasia, Broca, Aphasia, Wernicke, Aphasia, Fluent, Aphasia, Nonfluent
- Trial name
- RNAAT (NCT05274360)
- Testing
- Mobile evidence-based aphasia therapy, Conventional aphasia rehabilitation
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Institute for Bioengineering of Catalonia
Primary Progressive Nonfluent Aphasia
Transcranial Magnetic Stimulation in Nonfluent/Agrammatic Variant Primary Progressive Aphasia
Nonfluent/agrammatic variant primary progressive aphasia (nf/avPPA) is a fatal neurodegenerative disease that begins with isolated language deficits. There is currently no cure or treatment for this disease.
- Trial name
- NCT03153540
- Testing
- Active iTBS
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- University of British Columbia